PA
RIGL icon

Profund Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Profund Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453K Buy
16,743
+863
+5% +$29K 0.02% 584
2025
Q4 		$680K Buy
+15,880
New +$599K 0.02% 457
2014
Q2 		– Sell
-1,020
Closed -$40K – 1596
2014
Q1 		$40K Buy
+1,020
New +$36.4K ﹤0.01% 1581

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Profund Advisors's RIGL Position: Q1 2026 in Review

Profund Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 5.4% in Q1 2026, buying an estimated $29K and bringing the position to 16,743 shares worth $453K. The position accounts for 0.02% of the portfolio, ranked #584.

Profund Advisors first reported a position in RIGL in Q1 2014 and has held it in 3 quarters since. The position peaked at $680K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Profund Advisors held 16,743 shares of Rigel Pharmaceuticals worth $453K as of Q1 2026.
  • Profund Advisors bought 863 Rigel Pharmaceuticals shares in Q1 2026, an estimated $29K.
  • Rigel Pharmaceuticals made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #584 holding.
  • Profund Advisors first reported a position in Rigel Pharmaceuticals in Q1 2014 and has held it in 3 quarters since.
  • Profund Advisors's Rigel Pharmaceuticals position peaked at $680K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.